Image 2_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 7_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 6_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Data_Sheet_1_Global burden of drug use disorders by region and country, 1990–2021.docx by Shuyan Zhang (426593)

“…</p>Results<p>The global ASIR of DUDs showed a slight downward trend (EAPC = −0.26). The age-standardized DALY rate (per 100,000) significantly declined from 1990 to 2021 (EAPC = −1.44). …”

Table 1_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.xlsx by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 4_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 1_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Table_2_Global burden of drug use disorders by region and country, 1990–2021.docx by Shuyan Zhang (426593)

“…</p>Results<p>The global ASIR of DUDs showed a slight downward trend (EAPC = −0.26). The age-standardized DALY rate (per 100,000) significantly declined from 1990 to 2021 (EAPC = −1.44). …”

Image 8_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 5_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 3_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Image 9_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif by Yu-Syuan You (21288113)

“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”

Table_1_Global burden of drug use disorders by region and country, 1990–2021.docx by Shuyan Zhang (426593)

“…</p>Results<p>The global ASIR of DUDs showed a slight downward trend (EAPC = −0.26). The age-standardized DALY rate (per 100,000) significantly declined from 1990 to 2021 (EAPC = −1.44). …”

Data Sheet 1_Temperature extremes across elevation gradients: evidence from two German mountain observatories.pdf by Monica Ionita (6486275)

“…Temperature extremes have also changed markedly: cold extremes have declined significantly at both locations (e.g., the duration of cold spells has decreased by 16 days at Hohenpeißenberg and by 10 days at Zugspitze, over the period 1981–2024), while warm extremes exhibit a pronounced rise, especially in the Warm Spell Duration Index (WSDI), which has nearly doubled since the 1980s. …”

Droperidol is associated with reduced length of stay in the treatment of cannabinoid hyperemesis syndrome by Geoffrey S. Kelly (21537766)

“…After adjustments, droperidol use was associated with a reduced length of stay (mean ratio 0.76; 95% CI: 0.62 0.94; <i>P</i> = 0.01), decreased total medication administration (OR 0.34; 95% CI: 0.20–0.58; <i>P <</i>0.001) and decreased usage of opioids (OR 0.16; 95% CI: 0.07–0.39; <i>P <</i>0.001). …”

List of DEGs from neuronal cell analysis. by Sara Cuvertino (18892069)

“…In contrast with the epigenomic changes, the number of DEGs decrease as differentiation progresses. Our analysis reveals significant enrichment of differentially downregulated genes in areas containing putative enhancer regions with H3K4me1 loss. …”

Data Sheet 1_Silicon-iron modified biochar remediates cadmium and arsenic co-contaminated paddy soil by regulating cadmium and arsenic speciation.docx by Yao Chen (149006)

“…SMBC treatments reduced the bioavailable concentrations of Cd and As by 29.09–73.63% and 1.67–8.37%, respectively, transforming As(III) into less toxic As(V) and stabilizing soluble Cd into a more inert residual form. Compared to the control, SMBC significantly increased residual Cd concentrations by 2.94–16.17% (p < 0.05) and As(V) concentrations by 11.42–26.07% (p < 0.05). …”

Presentation 1_Open-Label-Placebos can reduce pain, but not indigestion during gluten challenge in chronic pain patients.pdf by Lena Paschke-Dahl (21477452)

“…</p>Results<p>In FMS patients, a significant interaction with instructions were observed (p = 0.048). …”

List of HipSci cell lines used in the study. by Sara Cuvertino (18892069)

“…In contrast with the epigenomic changes, the number of DEGs decrease as differentiation progresses. Our analysis reveals significant enrichment of differentially downregulated genes in areas containing putative enhancer regions with H3K4me1 loss. …”

List of DEGs from iPSC analysis. by Sara Cuvertino (18892069)

“…In contrast with the epigenomic changes, the number of DEGs decrease as differentiation progresses. Our analysis reveals significant enrichment of differentially downregulated genes in areas containing putative enhancer regions with H3K4me1 loss. …”